Alkermes plc (NASDAQ:ALKS) Shares Sold by Macquarie Group Ltd.

Posted by on Mar 7th, 2023

Macquarie Group Ltd. lowered its stake in Alkermes plc (NASDAQ:ALKS – Get Rating) by 0.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 425,124 shares of the company’s stock after selling 1,703 shares during the quarter. Macquarie Group Ltd. owned 0.26% of Alkermes worth $9,531,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALKS. Neo Ivy Capital Management acquired a new stake in Alkermes during the 2nd quarter worth $27,000. China Universal Asset Management Co. Ltd. acquired a new stake in Alkermes during the 3rd quarter worth $34,000. EverSource Wealth Advisors LLC acquired a new stake in Alkermes during the 3rd quarter worth $34,000. International Biotechnology Trust PLC acquired a new stake in Alkermes during the 2nd quarter worth $51,000. Finally, Quantbot Technologies LP acquired a new stake in Alkermes during the 3rd quarter worth $53,000. Institutional investors and hedge funds own 96.15% of the company’s stock.

Alkermes Stock Down 0.1 %

Shares of ALKS opened at $27.22 on Tuesday. The firm has a market cap of $4.47 billion, a P/E ratio of -28.35 and a beta of 0.60. Alkermes plc has a 12-month low of $21.75 and a 12-month high of $32.79. The company’s 50-day moving average price is $27.28 and its 200 day moving average price is $25.02. The company has a current ratio of 2.27, a quick ratio of 1.91 and a debt-to-equity ratio of 0.28.

Alkermes (NASDAQ:ALKS – Get Rating) last issued its quarterly earnings data on Thursday, February 16th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.09. The firm had revenue of $304.70 million for the quarter, compared to analyst estimates of $289.80 million. Alkermes had a negative net margin of 14.23% and a negative return on equity of 3.32%. Alkermes’s revenue was down 6.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 EPS. On average, sell-side analysts forecast that Alkermes plc will post -0.5 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on ALKS. HC Wainwright reaffirmed a “neutral” rating and set a $32.00 target price on shares of Alkermes in a research note on Friday, February 17th. Stifel Nicolaus lifted their price target on Alkermes to $30.00 in a report on Thursday, February 16th. Mizuho lifted their price target on Alkermes from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 22nd. Bank of America lifted their price target on Alkermes from $27.00 to $28.00 in a report on Sunday, January 8th. Finally, JPMorgan Chase & Co. reduced their price target on Alkermes from $33.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, December 6th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $30.11.

About Alkermes

(Get Rating)

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

Read More

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Get Rating).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.